HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

BOSTON, Nov. 09, 2023 -- HilleVax, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended...

Related Keywords

Russia ,Boston ,Massachusetts ,United States ,Japan ,Ukraine ,Japanese ,Rob Hershberg ,Shane Maltbie ,Takeda Vaccines Inc ,Hillevax Inc ,Nasdaq ,Exchange Commission ,Chief Executive Officer ,Norovirus Efficacy ,Safety Trial ,Takeda Vaccines ,Private Securities Litigation Reform Act ,Consolidated Statement ,Markets ,